(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Much work over the last two decades has firmly established that loss of cell cycle checkpoint regulation, and resultant unabated cellular proliferation, is an inherent characteristic of cancer. This loss may occur through aberration in any single component involved in signal transduction pathways that orchestrate checkpoint regulation, which may manifest through either a failure to activate the checkpoint or a failure to respond to the activated checkpoint. In normal cells, checkpoint pathways are activated when genetic or cellular homeostasis is compromised, and signals are then transduced to re-stabilize homeostasis, and, failing this, to activate the apoptotic machinery to induce a cellular suicidal response. This implies that both survival and cell death pathways are induced following checkpoint activation, and that the final decision is dependant on the net result of integrating the two sets of signals.
It is intriguing that checkpoint pathways are also critical in cancer therapy to provide an apoptotic stimulus when cellular damage induced by the therapeutic agent is detected by the sensor system. Therefore, it is not surprising that failure in pro-survival checkpoint response will render tumor cells hypersensitive to cytotoxics and, conversely, failure in pro-apoptotic checkpoint response will induce genetic instability and/or therapeutic resistance. Understanding the intricacies of checkpoint response is, therefore, central to the design of therapeutic regimen that will enhance antitumor effects. Although early versions of this design entail combination of cytotoxic agents with cell cycle or checkpoint inhibitors, a greater understanding of the concepts could make such combinations clinically more effective. The contributions in this book will consolidate the current state of knowledge on checkpoint responses that may lay the foundation for hypothesis-driven rational approaches in advancing the management of cancer.
The immediate attraction of the book to the scientific community is that it represents a timely opportunity to build upon existing concepts of checkpoints to expand our understanding of the inner workings of the critical checkpoint machinery. The present understanding has provided ample appreciation that response to checkpoint activation is manifested through coordinated inhibition of cyclin-dependent kinase (CDK) complexes in G1, S and/or the G2 phase in order to arrest the cell cycle. Kinase inhibition can occur through several mechanisms, including inhibitory phosphorylation of CDK, destruction of the cognate cyclins, and recruitment of CDK inhibitors from the INK and WAF1/CIP1 families. However, the wealth of information from recent discoveries needs to be examined critically to consolidate our conceptual knowledge of checkpoints. At the same time, there is acute awareness in the diversity of checkpoint response between cytotoxic agents, and this serves as a reminder of the magnitude of complexity that is inherent in checkpoint regulation. This volume is intended to bring the cancer research community closer toward an improved understanding of this regulation, how checkpoint abnormalities can impact negatively on cancer therapy, and emerging strategies to target checkpoint response as a therapeutic end-point.
Contents:
Part I: Circuitry of Checkpoint Response
Chapter 1
G1/S Checkpoint in Normal and Cancer Cells
(Bartek J, Copenhagen, Denmark)
Chapter 2
S-Phase Checkpoint
(Bunz F, Baltimore, MD)
Chapter 3
G2/M Checkpoint
(Stark GR, Cleveland, OH OR Lukas J, Copenhagen, Denmark)
Chapter 4
Mitotic Spindle Checkpoint
(Hoffman I, Heidelberg, Germany)
Chapter 5
ATM/Chk2 and ATR/Chk1 Pathways
(Dunphy WG, Pasadena, CA OR Kastan MB, Memphis, TN)
Chapter 7
INK/CIP inhibitor family members
(Xiong Y, Chapel Hill, NC OR Rudolph KL, Hannover, Germany)
Chapter 8
Centrosome in Checkpoint Response
(Muschel RJ, Philadelphia, PA OR Kramer A, Heidelberg, Germany)
Chapter 9
14-3-3 Family in Checkpoint Response
(Lee M-H, Houston, TX OR Hermeking H, Munich, Germany)
Chapter 10
BRCA1/2 in Checkpoint
(Deng CX, Bethesda, MD OR Boulton SJ, South Mimms, UK)
Chapter 11
Regulation of Checkpoint Response by CDC25
(Ducommun R, Toulouse, France)
Chapter 12
DNA Damage Recognition in Checkpoint Response
(Marini F, Milano, Italy)
Part II: Checkpoint Response and the Aetiology of Cancer
Chapter 13
Checkpoint Response and Cancer
(Nakanishi M, Nagoya, Japan OR Mollinari M, Milan, Italy)
Chapter 14
G1-Phase Cyclins and Cancer
(Hinds PW, Boston, MA OR Keyomarsi K, Houston, TX)
Chapter 15
Tumor Suppressor p53 and Cancer
(El-Deiry WS, Philadelphia, PA OR Zambetti GP, Memphis, TN)
Chapter 16
Rb dysfunction and Cancer
(Giordano A, Philadelphia, PA)
Chapter 17
Chk2 Status in Cancer
(Nevanlinna H, Helsinki, Finland)
Chapter 18
BRCA1/2 in Cancer
(Borgen PI, New York, NY)
Part III: Targeting Checkpoint Response in Cancer Therapy
Chapter 19
Checkpoint Response and the Balance Between Cell Survival and Cell Death
(Kaina B, Mainz, Germany OR Saito T, Tochigi, Japan)
Chapter 20
Targeting p53 for checkpoint activation
(Eastman A, Lebanon, NH OR Giardina C, Storrs, CT
Chapter 21
Targeting Checkpoint Kinases with Small molecule inhibitors
(Shapiro GI, Boston, MA OR Toogood PL, Ann Arbor, MI)
Chapter 22
p21-Dependent Checkpoint Response and Therapy
(Siddik ZH, Houston, TX)
Chapter 23
p27 Upregulation as a Target for Therapy-Mediated Cell Death
(Bast R, Houston, TX OR Malek NP, Hannover, Germany)
Chapter 24
Chk1/Chk2 as checkpoint targets
(Zhang H, Abbott Park, IL OR Grant S, Richmond)
Chapter 25
Mitotic Spindle Checkpoint as a Target
(Taylor SS, Manchester, UK OR Jackson JR, Collegeville, PA)
Chapter 26
Targeting Cdc25 in cancer therapy
(Rudolph J, Durham, NC)
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: March, 2012
Pages: 288
Weight: 552g
Availability: Available
Subcategories: Oncology, Pharmacology
Publisher recommends
From the same series
